Overview

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine maximum tolerated dose of Gleevec in combination with Chlorambucil in previously treated CLL patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jewish General Hospital
Collaborator:
Novartis Pharmaceuticals
Treatments:
Chlorambucil
Imatinib Mesylate